Publication date: Jul 29, 2026
The SCORPIO-PEP Phase 3 clinical trial demonstrated that ensitrelvir, a SARS-CoV-2 main protease inhibitor, significantly reduced the risk of symptomatic COVID-19 following household exposure. In a study involving 2041 participants, ensitrelvir achieved a 67% relative reduction in symptomatic cases compared to placebo over a 10-day period. The trial utilized a once-daily regimen administered within 72 hours of exposure and showed an overall efficacy rate of 98% against SARS-CoV-2 antibodies. Common adverse events associated with ensitrelvir included headache, diarrhea, and cough, alongside potential serious risks such as allergic reactions.
| Concepts | Keywords |
|---|---|
| Breastfeeding | Aged |
| Carbamazepine | Approval |
| Influenza | Cov |
| Japanese | Covid |
| June | Daily |
| Ensitrelvir | |
| Main | |
| Participants | |
| Placebo | |
| Postexposure | |
| Prophylaxis | |
| Protease | |
| Sars | |
| Trial | |
| United |
Semantics
| Type | Source | Name |
|---|---|---|
| pathway | KEGG | Viral replication |
| disease | MESH | sexually transmitted infections |
| disease | MESH | David |
| disease | MESH | included |
| disease | MESH | infection |
| disease | MESH | Headache |
| disease | MESH | influenza |
| disease | MESH | COVID-19 |
| disease | MESH | diarrhea |
| disease | MESH | cough |
| disease | MESH | Allergic reactions |
| disease | MESH | anaphylaxis |
| drug | DRUGBANK | Carbamazepine |
| drug | DRUGBANK | Phenytoin |
| drug | DRUGBANK | Rifampicin |
| drug | DRUGBANK | Simvastatin |
| drug | DRUGBANK | St. John’s Wort |
| disease | MESH | emergency |
| disease | MESH | Long Covid |
(Visited 8 times, 1 visits today)